New drug trial aims to control dangerous bleeding disorder

NCT ID NCT05653349

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding a new drug called ianalumab to standard steroid treatment helps adults with primary immune thrombocytopenia (ITP) maintain safer platelet counts and reduce bleeding risk. The trial involves 226 participants who will receive either ianalumab or a placebo along with their steroid treatment. Researchers are measuring how long patients can keep their platelet counts above a critical threshold without needing additional rescue treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Med Center

Boston, Massachusetts, 02215, United States
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Clinical Research Alliance

Lake Success, New York, 11042, United States
Community Cancer Institute

Clovis, California, 93611, United States
Community Cancer Trials of Utah

Ogden, Utah, 84405, United States
Compassionate Care Res Group Inc

Fountain Valley, California, 92708, United States
DH Cancer Research Center LLC

Margate, Florida, 33063, United States
Hematology Oncology Association of Rockland

Nyack, New York, 10960, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
Mays Cancer Ctr Uthsa Mdacc

San Antonio, Texas, 78229, United States
Metro Minnesota CCOP

Saint Louis Park, Minnesota, 55416, United States
Michigan Center of Medical Research

Farmington Hills, Michigan, 48334, United States
Novartis Investigative Site

CABA, Buenos Aires, 1280, Argentina
Novartis Investigative Site

CABA, Buenos Aires, C1414DRK, Argentina
Novartis Investigative Site

San Miguel Tucuman, Tucumán Province, T4000DPK, Argentina
Novartis Investigative Site

Caba, C1015ABO, Argentina
Novartis Investigative Site

Caba, C1039AAC, Argentina
Novartis Investigative Site

Córdoba, 5000, Argentina
Novartis Investigative Site

Garran, Australian Capital Territory, 2605, Australia
Novartis Investigative Site

Wooloongabba, Queensland, 4102, Australia
Novartis Investigative Site

Clayton, Victoria, 3168, Australia
Novartis Investigative Site

Melbourne, Victoria, 3004, Australia
Novartis Investigative Site

Innsbruck, Tyrol, 6020, Austria
Novartis Investigative Site

Salzburg, 5020, Austria
Novartis Investigative Site

Roeselare, West-Vlaanderen, 8800, Belgium
Novartis Investigative Site

Brasschaat, 2930, Belgium
Novartis Investigative Site

Bruges, 8000, Belgium
Novartis Investigative Site

Leuven, 3000, Belgium
Novartis Investigative Site

Plovdiv, 4002, Bulgaria
Novartis Investigative Site

Sofia, 1431, Bulgaria
Novartis Investigative Site

Beijing, Beijing Municipality, 100044, China
Novartis Investigative Site

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site

Shenzhen, Guangdong, 518037, China
Novartis Investigative Site

Shijiazhuang, Hebei, 050000, China
Novartis Investigative Site

Luoyang, Henan, 471003, China
Novartis Investigative Site

Zhengzhou, Henan, 450003, China
Novartis Investigative Site

Wuhan, Hubei, 430022, China
Novartis Investigative Site

Changzhou, Jiangsu, 213004, China
Novartis Investigative Site

Nanchang, Jiangxi, 330006, China
Novartis Investigative Site

Chengdu, Sichuan, 610041, China
Novartis Investigative Site

Kunming, Yunnan, 650101, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310006, China
Novartis Investigative Site

Bengbu, 233004, China
Novartis Investigative Site

Dalian, 116000, China
Novartis Investigative Site

Tianjin, 300020, China
Novartis Investigative Site

Ostrava, Poruba, 708 52, Czechia
Novartis Investigative Site

Brno, 625 00, Czechia
Novartis Investigative Site

Prague, 100 34, Czechia
Novartis Investigative Site

Prague, 128 08, Czechia
Novartis Investigative Site

Caen, 14033, France
Novartis Investigative Site

Chambéry, 73000, France
Novartis Investigative Site

Le Mans, 72000, France
Novartis Investigative Site

Lille, 59037, France
Novartis Investigative Site

Rennes, 35033, France
Novartis Investigative Site

Frankfurt am Main, Hesse, 60590, Germany
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Jena, Thuringia, 07740, Germany
Novartis Investigative Site

Dresden, 01307, Germany
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Giessen, 35392, Germany
Novartis Investigative Site

New Territories, Hong Kong, 000000, Hong Kong
Novartis Investigative Site

Hong Kong, Hong Kong
Novartis Investigative Site

Debrecen, Hajdu Bihar Megye, 4032, Hungary
Novartis Investigative Site

Budapest, H-1083, Hungary
Novartis Investigative Site

Ahmedabad, Gujarat, 380013, India
Novartis Investigative Site

Rishikesh, Uttarakhand, 249203, India
Novartis Investigative Site

Kolkata, West Bengal, 700094, India
Novartis Investigative Site

Bologna, BO, 40138, Italy
Novartis Investigative Site

Florence, FI, 50134, Italy
Novartis Investigative Site

Roma, RM, 00168, Italy
Novartis Investigative Site

Trieste, TS, 34129, Italy
Novartis Investigative Site

Vicenza, VI, 36100, Italy
Novartis Investigative Site

Nagakute, Aichi-ken, 480-1195, Japan
Novartis Investigative Site

Shibukawa, Gunma, 377-0280, Japan
Novartis Investigative Site

Sapporo, Hokkaido, 060-8604, Japan
Novartis Investigative Site

Okayama, Okayama-ken, 7011192, Japan
Novartis Investigative Site

Iruma-gun, Saitama, 3500495, Japan
Novartis Investigative Site

Chiba, 260-0852, Japan
Novartis Investigative Site

Fukuoka, 815-8555, Japan
Novartis Investigative Site

Gifu, 5008513, Japan
Novartis Investigative Site

Osaka, 543-8555, Japan
Novartis Investigative Site

Kuching, Sarawak, 93586, Malaysia
Novartis Investigative Site

George Town, 10050, Malaysia
Novartis Investigative Site

Johor Bahru, 80100, Malaysia
Novartis Investigative Site

Kuala Selangor, 68000, Malaysia
Novartis Investigative Site

Mexico City, Mexico City, 06720, Mexico
Novartis Investigative Site

Monterrey, Nuevo León, 64460, Mexico
Novartis Investigative Site

Grålum, 1714, Norway
Novartis Investigative Site

Bucharest, 030171, Romania
Novartis Investigative Site

Singapore, 119074, Singapore
Novartis Investigative Site

Singapore, 169608, Singapore
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28046, Spain
Novartis Investigative Site

Murcia, 30008, Spain
Novartis Investigative Site

Salamanca, 37007, Spain
Novartis Investigative Site

Seville, 41013, Spain
Novartis Investigative Site

Bangkok, 10330, Thailand
Novartis Investigative Site

Bangkok, 10700, Thailand
Novartis Investigative Site

Chiang Mai, 50200, Thailand
Novartis Investigative Site

Samsun, Atakum, 55200, Turkey (Türkiye)
Novartis Investigative Site

Aydin, Efeler, 09100, Turkey (Türkiye)
Novartis Investigative Site

Istanbul, Fatih, 34098, Turkey (Türkiye)
Novartis Investigative Site

Birmingham, West Midlands, B15 2TH, United Kingdom
Novartis Investigative Site

London, W12 0HS, United Kingdom
Novartis Investigative Site

Nottingham, NG5 1PB, United Kingdom
Novartis Investigative Site

Hanoi, 100000, Vietnam
Novartis Investigative Site

Ho Chi Minh City, 70000, Vietnam
Oncology Care Associates

Bethesda, Maryland, 20817, United States
Parkview Research Center

Fort Wayne, Indiana, 46845, United States
Rhode Island Hospital

Providence, Rhode Island, 02903, United States
STAT Research Inc

Dayton, Ohio, 45402, United States
St Vincent Frontier Cancer Center

Billings, Montana, 59102, United States
Uni of Chi Medi Ctr Hema and Onco

Chicago, Illinois, 60637, United States
University of Colorado Anschutz

Aurora, Colorado, 80045, United States
Yuma Regional Medical Center

Yuma, Arizona, 85349, United States

Conditions

Explore the condition pages connected to this study.

PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)